Trial · NCT01371981
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm A | 45.64 | 95% Confidence Interval 41.34 to 49.83 | percentage of patients | |
| Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm B | 46.95 | 95% Confidence Interval 42.69 to 51.09 | percentage of patients | |
| EFS for Patients on Arm C, Cohort 1 | Arm C (Cohort 1) | 25.00 | 95% Confidence Interval 6.01 to 50.48 | percentage of patients | |
| EFS for Patients on Arm C, Cohort 2 | Arm C (Cohort 2) | 56.12 | 95% Confidence Interval 37.33 to 71.28 | percentage of patients | |
| EFS for Patients on Arm C, Cohort 3 | Arm C (Cohort 3) | 58.18 | 95% Confidence Interval 42.30 to 71.11 | percentage of patients | |
| Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm A | 65.04 | 95% Confidence Interval 60.75 to 68.98 | percentage of patients | |
| Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm B | 68.45 | 95% Confidence Interval 64.33 to 72.21 | percentage of patients | |
| OS for Patients on Arm C, Cohort 1 | Arm C (Cohort 1) | 41.67 | 95% Confidence Interval 15.25 to 66.53 | percentage of patients | |
| OS for Patients on Arm C, Cohort 2 | Arm C (Cohort 2) | 64.77 | 95% Confidence Interval 45.37 to 78.77 | percentage of patients | |
| OS for Patients on Arm C, Cohort 3 | Arm C (Cohort 3) | 61.84 | 95% Confidence Interval 44.09 to 75.42 | percentage of patients | |
| Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm A | 46.67 | 95% Confidence Interval 42.36 to 50.86 | percentage of patients | |
| Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations | Arm B | 46.65 | 95% Confidence Interval 42.39 to 50.80 | percentage of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm A | 0.8819 | 95% Confidence Interval 0.8522 to 0.9075 | Proportion of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm B | 0.9217 | 95% Confidence Interval 0.8967 to 0.9423 | Proportion of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm C (Cohort 1) | 0.9167 | 95% Confidence Interval 0.6152 to 0.9979 | Proportion of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm C (Cohort 2) | 0.9394 | 95% Confidence Interval 0.7977 to 0.9926 | Proportion of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm C (Cohort 3) | 0.9149 | 95% Confidence Interval 0.7962 to 0.9763 | Proportion of patients | |
| Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy | Arm D | 0.0239 | 95% Confidence Interval 0.0110 to 0.0450 | Proportion of patients | |
| Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II | Arm A | 0.5000 | 95% Confidence Interval 0.3830 to 0.6170 | Proportion of patients | |
| Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II | Arm B | 0.5238 | 95% Confidence Interval 0.4119 to 0.6340 | Proportion of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01371981/results